Browse by ▼

Life Technologies Corporation

  • Is Life technologies over valued

    By Saurabh Mishra - May 24, 2013 | Tickers: A, LIFE, VIVO

    On April 15th 2013, Thermo fisher announced to acquire Life technologies (LIFE) for $13.6 billion plus the assumption of net debt of around $2.2 billion. This report analyses the growth of Life technologies and concludes if LIFE is overvalued or under valued

    About Life Technologies

    Life technologies is a company that produces systems and reagents that enable and simplify the biological research of genes proteins and cells more »

  • This Biotech Giant Is Continuing Its Growth via M&A

    By Peter Pham - May 13, 2013 | Tickers: ILMN, LIFE, TMO

    A group representing some of the biggest private equity firms in the world, the Blackstone Group, Carlyle Group, KKR, and Singapore’s Temasek Holdings are eyeing California based bio-tech firm Life Technologies (NASDAQ: LIFE). They forwarded a bid of $62 per share, which values the firm at $11 billion. But, the analytical and laboratory equipment behemoth, Thermo Fisher Scientific (NYSE: TMO) came forward with a much higher bid of $75 more »

  • Top Three Performing NASDAQ 100 Stocks for 2013

    By Naomi Warmate-Igwe - May 1, 2013 | Tickers: CELG, LIFE, VRTX

    It should come as no surprise that year to date, the top three performing NASDAQ 100 stocks come from companies in the health care sector. Through April 26th, those companies were Vertex Pharmaceuticals (NASDAQ: VRTX) Celgene Corporation (NASDAQ: CELG) and Life Technologies (NASDAQ: LIFE). As many analysts have predicted, the health care sector is performing exceptionally in 2013, asU.S. firms scramble for their piece of the pie in more »

  • This Deal Brings Benefits Along With a Huge Debt

    By Shas Dey - April 29, 2013 | Tickers: ILMN, LIFE, RHHBY, TMO

    The rumors have finally been put to rest. After three months of a bidding war, Thermo Fisher Scientific (NYSE: TMO) ultimately beat other contenders to acquire Life Technologies (NASDAQ: LIFE) for $76 per share, or approximately $13.6 billion (plus net debt at close).

    This transaction, expected to be completed in 2014, is expected to propel the growth of Thermo Fisher in the area of genetic analysis and molecular diagnostics more »

  • Where's the Profit in this Medical Technology Merger?

    By Mike Thiessen - April 28, 2013 | Tickers: A, LIFE, TMO

    After a long takeover battle, Thermo Fisher Scientific (NYSE: TMO) has agreed on a takeover deal with merger partner, Life Technologies (NASDAQ: LIFE). The cash-and-debt deal would cost roughly $13.6 billion and result in Thermo's assumption of over $2 billion in Life's debt. 

    This deal is notable for several reasons. Among other things, Thermo beat out a consortium of private equity firms with an apparently superior bid more »

  • Forget About Life, Check out This Stock

    By Marshall Hargrave - April 22, 2013 | Tickers: A, LIFE, PKI, TMO

    The big news in the medical service and device sector is the speculated buyout of Life Technologies (NASDAQ: LIFE). However, I believe investors could snatch up Agilent Technologies (NYSE: A) for a "good" price amid the hype surrounding Life.
     
    Agilent provides bio-analytic and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries, meaning it has a bit more of a diversified portfolio, serving not only the more »

  • Thermo Fisher – Life Technologies Deal Brings Benefits Along With A Huge Debt

    By Shas Dey - April 18, 2013 | Tickers: ILMN, LIFE, RHHBY, TMO

    On 15th April, Thermo Fisher Scientific (NYSE: TMO) announced that it would acquire Life Technologies (NASDAQ: LIFE) for $76 per share, 12% above its 12thApril share price of $68.

    The Deal

    After months of speculation of takeover, Life Technologies accepted Thermo Fisher’s bid over an offer from Sigma-Aldrich and a $65 per share bid from a consortium including Blackstone, Carlyle, KKR and Temasek Holdings. The price more »

  • This Huge Bidding War Is a Speculative Play

    By Anh HOANG - April 15, 2013 | Tickers: A, LIFE, TMO

    Since the beginning of the year, shareholders of Life Technologies (NASDAQ: LIFE) must be quite happy as its share price advanced significantly, from $49 per share to nearly $67 per share, a four-month gain of 36.7%. Recently, the company received a bid of $65 per share from a buyout group, which includes Blackstone Group, Carlyle Group, KKR & Co, and Temasek Holdings. However, Thermo Fisher Scientific (NYSE: TMO) placed a more »

  • These Companies Will Rise on M&A

    By Mohsin Saeed - April 13, 2013 | Tickers: DELL, LIFE, TMO

    The healthcare sector has given its investors pretty good returns in the last few quarters. Big pharmaceuticals have given solid capital appreciation on top of their solid dividend yields, but the surprise package has been the biotechnology industry. The industry has seen significant capital appreciation due to a large number of drugs getting FDA approval. The big pharmaceutical companies interested in promising candidates have also positively affected the stocks of more »

  • These Companies Will Rise on M&A

    By Mohsin Saeed - April 11, 2013 | Tickers: DELL, LIFE, TMO

    The healthcare sector has given its investors pretty good returns in the last few quarters. Big Pharmaceuticals have given solid capital appreciations on top of their solid dividend yields but the surprise package has been the biotechnology industry. The industry has seen significant capital appreciation due to a large number of drugs getting FDA approval. The big pharmaceutical companies interested in promising candidates have also positively affected the stock price more »

  • Investing in a Cheap Life

    By Marshall Hargrave - March 8, 2013 | Tickers: JNJ, LIFE, MRK, ONXX, SGEN

    Life Technologies (NASDAQ: LIFE) appears to have lost its buyout premium, but is the stock still worth investing in? The stock fell 7% earlier this week after reports that the buyout buzz for the company was cooling off. The maker of genetic testing equipment was previously reported to have engaged Deutsche and Moelis & Company to help shop around. Meanwhile, parties potentially interested in scooping up the company included Blackstone and more »

  • Three Reasons to Worry and One Theme That Can Outperform

    By Lee Samaha - February 22, 2013 | Tickers: ACT, COV, ILMN, LIFE, MYL

    Occasionally some of my friends ask me why I am hedged and market neutral in my investing. My answer is always the same. I invest for the long term, and the macro-environment remains very dangerous right now. I am confident in my ability to pick a portfolio that can outperform the market, but I can’t predict what is going to happen in the global economy, and the evidence is more »

  • Searching for the Next Franchise in Diagnostic Testing

    By Robert Hanley - January 25, 2013 | Tickers: GNMK, LIFE, DGX

    Ever since the human genome was completely sequenced in 2001, investment opportunities have abounded in the diagnostic testing industry, as exciting, new technologies have been built around this important scientific discovery.  The increasingly recurring nature of the testing business, and its strong profit margins, have brought private equity firms to the sector in search of buyouts.  The latest target is Life Technologies (NASDAQ: LIFE), which recently announced that it was more »

  • Top News on January 18 That You Might Have Missed!

    By Brian Nichols - January 19, 2013 | Tickers: INTC, LIFE, NES.DL, SNE, BA

    What happened today, why does it matter, and what could it mean for the future? Here's my take on Thursday’s company-specific and broader industry news that could have long-lasting effects on your portfolio.

    U.S. Secretary of Transportation changes his mind rather quickly

    Last week, the U.S. Secretary of Transportation Wood, said that Boeing's (NYSE: BA) 787 Dreamliner was safe and that he would fly more »

  • The Smart Money Has Been Eying the Future of DNA Sequencing: Should You?

    By Brendan O'Boyle - January 8, 2013 | Tickers: ILMN, LIFE, RHHBY

    Roche (NASDAQOTH: RHHBY) has a remarkable history of making attractive and well-timed acquisitions.  In 2009 they purchased Genentech and bought one of the most attractive companies on the market as blood ran through the streets. Recently Roche has turned its interest to a little known sequencing company named Illumina (NASDAQ: ILMN), but over this weekend they appear to have withdrawn the offer for a second time.

    In this context, it more »

  • Which Hospital Operators Will Thrive Under ObamaCare?

    By Anh HOANG - November 28, 2012 | Tickers: CYH, HCA, HMA, LIFE, LPNT

    At the end of 2011, when I was looking for investment opportunities in the US, I stumbled onto one decent hospital operator that had continued to increase operating cash flow. However, I did not initiate a position because of its high leverage level. That company is Community Health Systems (NYSE: CYH). When I first looked at it, CYH was trading for only $16 - $17 per share. Now, I feel I more »

  • What the Bioeconomy Means for Investors

    By Maxxwell A.R. Chatsko - November 27, 2012 | Tickers: AMRS, CERE, LIFE, MON, MYGN, SZYM | Editor's Choice

    On April 1, the White House released the National Bioeconomy Blueprint (opens PDF) that outlined the importance of transitioning health/life science, chemical production, agriculture, and other industries into the 21st century. Yes, it was April Fool’s Day. No, the White House wasn’t joking.

    Despite being lost in the midst of an election year the message was clear: an American bioeconomy can transform the world. The report more »

  • Billionaire John Paulson’s Latest Stock Picks

    By Meena Krishnamsetty - November 17, 2012 | Tickers: AU, DLPH, EQIX, HIG, LIFE

    One of the most revered names in the business, billionaire hedge fund manager John Paulson is famous for his lucrative bets against subprime mortgages in the mid-2000s. Paulson earned a $4.9 billion payout in 2010, breaking records in the hedge fund industry. Lately, however, Paulson has had to convince investors that his fund is still on the straight and narrow path—his major funds posted double-digit losses over the more »

  • Sangamo's 'Functional Cure' of HIV Approach May Work On Other Diseases

    By Rex Graham - November 16, 2012 | Tickers: LIFE, SGMO

    The odds of a major advance in the fight against HIV/AIDS have improved with the recent announcement by Sangamo Biosciences (NASDAQ: SGMO) that its gene therapy treatment has achieved a “functional cure” for some HIV patients in its Phase 1 clinical trials.


    (Photo: Eva Kolenko)


    Tim Brown, the famous “Berlin patient” and first person cured of HIV, appeared at the HIV Cure Forum in Palm Springs and West Hollywood more »

  • North Run Capital’s Top Stock Picks

    By Meena Krishnamsetty - November 13, 2012 | Tickers: ADBE, CIT, HNT, LIFE, XRX

    North Run Capital, which is managed by Thomas Ellis and Todd Hammer, filed its 13F for the third quarter of 2012 with the SEC earlier this month. These filings disclose many of a hedge fund’s or other major investor’s long equity positions to the general public, and investors can use this data to inform their decisions. We think that it can be a good idea to use these more »

  • Page 1 of 2